# Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy

> **NCT00415363** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 109 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Small Cell Lung Cancer

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00415363
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2020-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415363, "Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00415363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*